Literature DB >> 21811807

Review of the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial: warfarin versus dabigatran.

Christopher Ingelmo1, Oussama Wazni.   

Abstract

Entities:  

Year:  2011        PMID: 21811807     DOI: 10.1007/s11886-011-0203-4

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


× No keyword cloud information.
  18 in total

1.  2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on Dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.

Authors:  L Samuel Wann; Anne B Curtis; Kenneth A Ellenbogen; N A Mark Estes; Michael D Ezekowitz; Warren M Jackman; Craig T January; James E Lowe; Richard L Page; David J Slotwiner; William G Stevenson; Cynthia M Tracy; Valentin Fuster; Lars E Rydén; David S Cannom; Harry J Crijns; Anne B Curtis; Kenneth A Ellenbogen; Jonathan L Halperin; G Neal Kay; Jean-Yves Le Heuzey; James E Lowe; S Bertil Olsson; Eric N Prystowsky; Juan Luis Tamargo; L Samuel Wann; Alice K Jacobs; Jeffrey L Anderson; Nancy Albert; Mark A Creager; Steven M Ettinger; Robert A Guyton; Jonathan L Halperin; Judith S Hochman; Frederick G Kushner; Erik Magnus Ohman; William G Stevenson; Clyde W Yancy
Journal:  Circulation       Date:  2011-02-14       Impact factor: 29.690

Review 2.  Dabigatran etexilate: a new oral thrombin inhibitor.

Authors:  Graeme J Hankey; John W Eikelboom
Journal:  Circulation       Date:  2011-04-05       Impact factor: 29.690

3.  Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial.

Authors:  John W Eikelboom; Lars Wallentin; Stuart J Connolly; Mike Ezekowitz; Jeff S Healey; Jonas Oldgren; Sean Yang; Marco Alings; Scott Kaatz; Stefan H Hohnloser; Hans-Christoph Diener; Maria Grazia Franzosi; Kurt Huber; Paul Reilly; Jeanne Varrone; Salim Yusuf
Journal:  Circulation       Date:  2011-05-16       Impact factor: 29.690

4.  Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion.

Authors:  Rangadham Nagarakanti; Michael D Ezekowitz; Jonas Oldgren; Sean Yang; Michael Chernick; Timothy H Aikens; Greg Flaker; Josep Brugada; Gabriel Kamensky; Amit Parekh; Paul A Reilly; Salim Yusuf; Stuart J Connolly
Journal:  Circulation       Date:  2011-01-03       Impact factor: 29.690

5.  Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation.

Authors:  Shimoli V Shah; Brian F Gage
Journal:  Circulation       Date:  2011-05-23       Impact factor: 29.690

Review 6.  Dabigatran etexilate: the first oral anticoagulant available in the United States since warfarin.

Authors:  Arlene Tran; Angela Cheng-Lai
Journal:  Cardiol Rev       Date:  2011 May-Jun       Impact factor: 2.644

7.  Incidence of and risk factors for atrial fibrillation in older adults.

Authors:  B M Psaty; T A Manolio; L H Kuller; R A Kronmal; M Cushman; L P Fried; R White; C D Furberg; P M Rautaharju
Journal:  Circulation       Date:  1997-10-07       Impact factor: 29.690

8.  Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation.

Authors:  Robert G Hart; Lesly A Pearce; Maria I Aguilar
Journal:  Ann Intern Med       Date:  2007-06-19       Impact factor: 25.391

9.  Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction.

Authors:  D L Dries; D V Exner; B J Gersh; M J Domanski; M A Waclawiw; L W Stevenson
Journal:  J Am Coll Cardiol       Date:  1998-09       Impact factor: 24.094

10.  The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study.

Authors:  A D Krahn; J Manfreda; R B Tate; F A Mathewson; T E Cuddy
Journal:  Am J Med       Date:  1995-05       Impact factor: 4.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.